Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Nifty, Bank Nifty outlook & stock recommendations by Motilal Oswal
Chandan Taparia of Motilal Oswal Financial Services expects Nifty and Bank Nifty to trade with a weak bias as long as they remain below 23,850 and 57,250, respectively.
Worst is behind us, markets could hit new highs in 6-12 months: Envision’s Nilesh Shah
Nilesh Shah, Founder of Envision Capital, remains positive on digital platforms, defence, aerospace and consumer discretionary sectors, citing long-term domestic growth drivers. Shah expects stronger earnings, policy reforms and foreign investor participation to support markets, while also identifying opportunities linked to GLP-1 drugs, nutrition products and healthcare themes.
RBI Governor urges banks to treat MSMEs as long-term business partners
Reserve Bank Governor Sanjay Malhotra on Monday asked banks and lending institutions to internalise a fundamental reorientation in their approach towards MSMEs, and view them as long-term business partners rather than just a regulatory obligation. He said MSMEs collectively contribute 31 per cent of GDP, account for approximately 35 per cent of manufacturing output, and represent close to half of India's merchandise exports, while sustaining livelihoods for over 32 crore people. He also asked MSMEs to take ownership of growth by investing in technology, R&D and innovation as consumer preferences and expectations evolve, engage actively with RBI through their instruments and build and sustain relationships with your stakeholders creditors, suppliers and customers.
Sun Pharmaceutical among 5 Nifty stocks showing bullish RSI upswing
Five Nifty50 stocks featured in the RSI Trending Up scan on June 17 after showing improving momentum. The RSI moved above the 50 mark from lower levels, signalling strengthening price action, improving sentiment and potential short-term buying opportunities for traders tracking bullish technical setups.
Blue Star: Nirmal Bang Maintains Buy on Strong Fundamentals, Long-Term Growth Drivers— Check Target Price
Blue Star's shares are likely to be in focus after Nirmal Bang reiterated its Buy' rating on the stock, citing strong fundamentals and long-term growth visibility.
P&G India flags pressure on consumer demand, input costs
Procter and Gamble India sees rising costs and softening urban demand, with company executives saying inflation will impact consumer spending. However, despite near-term challenges, P&G maintains a positive long-term outlook for India.
PPF Investors, Take Note: Extending Your Account Could Lead Your Corpus To Over Rs 1 Crore
For long-term savers, a PPF extension can turn an already substantial corpus into an even larger retirement fund.
Why Bajaj Finserv AMC is bullish on banks, NBFCs and the Indian market
Nimesh Chandan, Chief Investment Officer at Bajaj Finserv AMC, said the recent correction has created opportunities in select gold financing companies. However, the fund house remains relatively cautious on jewellery stocks and is more constructive on gold financiers from a long-term perspective.
Anupam Rasayan becomes first company to commercialise ETFA, eyes $500 million market
Anupam Rasayan said it will continue to invest in advanced process technologies, research capabilities and sustainable manufacturing practices as part of its long-term growth strategy.
Manipal Health leases Bengaluru hospital asset on nearly 30-year pact
Manipal Health Enterprises has secured a large hospital building in Bengaluru on a long-term lease. The deal spans almost 30 years, with a total rental commitment of around Rs 500 crore. This expansion follows recent acquisitions and property deals. The company is growing its network to meet rising healthcare demand.
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplash
Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic demand and positive global healthcare trends. Analysts see long-term growth potential from aging populations and innovation. Emerging opportunities from supply chain diversification away from China also present a positive outlook for Indian pharmaceutical companies.
Concord Biotech shares gain 5% after bagging USFDA approval for $500 million drug
According to Concord Biotech, this development aligns directly with its long-term growth strategy, aimed at reinforcing its commercial footprint across both US and international markets.